Announcing the results of the research on the coronavirus Delta variant, Israel was at the top of the health agenda. While it was learned that the study in question was not yet peer-reviewed, it was learned that samples taken from 11 thousand people infected with the coronavirus variant were analyzed.
In the samples, it was determined that the 3rd doses reduced the viral load 4 times. We have written the important information about the third vaccine made in Israel for you in the continuation of our news.
In the new study, it was stated that the 3rd dose vaccine, known as the Pfizer booster vaccine, significantly reduced the viral load in patients infected with the Delta variant and also reduced the risk of transmission.
As a result of the research, it was concluded that approximately 6 months after the second dose of the coronavirus vaccine, the effectiveness of the vaccine in reducing the viral load was lost. On the other hand, it was concluded that the 3rd dose of coronavirus vaccine reduced the viral load by 4 times.
It was learned that 11,000 PCR swab tests performed on patients infected with the delte variant were analyzed. The patients in question were examined in three separate groups: those who had never been vaccinated, those who were infected within 6 months after the second friendly coronavirus vaccine, and those who were infected after the booster application.
Detailed information about the importance and results of the study on the 3rd dose coronavirus vaccine in Israel is given in the continuation of our news. Here are the curious and important points about the 3 doses of coronavirus vaccine that reduces the risk of transmission.
What was discovered in the study was that the effectiveness of the coronavirus vaccine relative to viral load gradually decreased over time, reaching a high level similar to that of an unvaccinated person after 6 months. However, it was said that they also discovered that the 3rd dose coronavirus vaccine, which is a booster, reduces the viral load by 4 times and restores it.
